At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 22, 2026 at 09:00 ET
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showing pelareorep expands pre-existing tumor-reactive immune cells and activates anti-tumor responses in KRAS-mutant pancreatic cancer and early-stage breast cancer. The data are mechanistic and non-clinical, with no new efficacy results or regulatory milestones disclosed.
- Translational data from GOBLET (pancreatic cancer) and AWARE-1 (breast cancer) to be presented at ASCO 2026 (May 29-June 2).
- Data show pelareorep induces antiviral immune response, expands virus-specific T cells, and activates tumor-specific T cells.
- In pancreatic cancer, expansion of pre-existing TIL clones in blood correlated with reductions in tumor volume.
- T-cell receptor sequencing confirmed expansion of mutant KRAS-specific T-cell clones.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access